About
Products
Knolens
KnolScapes
Knolens
Knolens SLR
Knolens
KnolQuest
Knolens
Edge
Knolens
DataNexus
Platform
Solutions
KnolSights
Experience Knolens
Neurocrine Biosciences Initiates Phase 3 Trial for NBI-1117568 in Schizophrenia
Neurocrine Biosciences has initiated a Phase 3 registrational program for NBI-1117568, an oral muscarinic M4 selective receptor agonist, as a potentia...
Copyright © 2025. All rights reserved
About
Terms of Service
Privacy Policy
Home/
KnloSights/
Clinical Trial Updates/
Neurocrine Biosciences Initiates Phase 3 Trial for NBI-1117568 in Schizophrenia